Sequencing of Cabazitaxel and Abiraterone Acetate after Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices

Clinical Genitourinary Cancer

Volumn 13, Issue 4, 2015, Pages 309-318

  Sonpavde, Guru ^a   Bhor, Menaka ^b   Hennessy, Daniel ^c   Bhowmik, Debajyoti ^b   Shen, Liji ^c   Nicacio, Leonardo ^c   Rembert, Debra ^b   Yap, Mark ^b   Schnadig, Ian ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b McKesson   (United States)

^c SANOFI   (France)

^d Compass Oncology ^*  (United States)

Author keywords

Clinical outcomes; Electronic health record; mCRPC; Retrospective; Treatment sequence

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; ELECTRONIC MEDICAL RECORD; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; BONE NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; VERY ELDERLY;

ABIRATERONE ACETATE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84936986004     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.12.019     Document Type: Article

References (22)

1. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
2. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
3. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
4. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
5. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
6. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
7. T.M. Beer, A.J. Armstrong, and D.E. Rathkopf Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
8. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
9. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
10. C. Parker, S. Nilsson, and D. Heinrich Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
11. National Institutes of Health. NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy, updated June 1, 2014. Available at: http://www.cancer.gov/newscenter/newsfromnci/2013/E3805. Accessed: January 17, 2015.
12. A.J. Armstrong, E.S. Garrett-Mayer, and Y.C. Yang A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403
13. D.P. Petrylak, K. Fizazi, and C.N. Sternberg Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial Ann Oncol 23 suppl 9 2012 ixe1 30 abstract LBA24
14. J. Goyal, P. Nuhn, and P. Huang The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer BJU Int 110 2012 E575 E582
15. A. Angelergues, D. Maillet, and A. Flechon Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: sequencing might matter J Clin Oncol 31 15 suppl 2013 abstract 5063
16. Y. Loriot, C. Massard, and L. Albiges Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity J Clin Oncol 30 5 suppl 2012 abstract 213
17. C. Buonerba, G.R. Pond, and G. Sonpavde Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer Future Oncol 9 2013 889 897
18. R.J. van Soest, E.S. de Morree, and L. Shen Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study Eur Urol 66 2014 330 336
19. D. Azria, C. Massard, and D. Tosi An ambispective observational study evaluating safety and efficacy of abiraterone acetate in the French Temporary Authorizations for Use (ATU): predictive parameters of response J Clin Oncol 30 5 suppl 2012 abstract 149
20. Y. Loriot, D. Bianchini, and E. Ileana Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
21. J. Mezynski, C. Pezaro, and D. Bianchini Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947
22. D. Mukherji, C.J. Pezaro, D. Bianchini, A. Zivi, and J.S. de Bono Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel J Clin Oncol 30 5 suppl 2012 abstract 17